@article{1121,
  author = {Nora Franzen and Wim H. van Harten and Valesca P. Retèl and Peter Loskill and Janny van den Eijnden-van Raaij and Maarten IJzerman},
  title = {Impact of organ-on-a-chip technology on pharmaceutical R&D costs},
  abstract = {Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.},
  year = {2019},
  journal = {Drug Discovery Today},
  volume = {24},
  pages = {1720-1724},
  month = {2019-09-01},
  issn = {1359-6446},
  url = {https://www.sciencedirect.com/science/article/pii/S135964461930042X},
  doi = {10.1016/j.drudis.2019.06.003},
  language = {en},
}